Inhibitory effects of Shouseiryu-to on two-stage carcinogenesis. II. Anti-tumor-promoting activities of lignans from Asiasarum heterotropoides var. mandshuricum

Biological and Pharmaceutical Bulletin

Volumn 20, Issue 7, 1997, Pages 776-780

  Takasaki, Midori ^a   Konoshima, Takao ^a   Yasuda, Ichiro ^b   Hamano, Tomoko ^b   Tokuda, Harukuni ^c  

^a KYOTO PHARMACEUTICAL UNIVERSITY   (Japan)

^b TOKYO METROPOLITAN INSTITUTE OF PUBLIC HEALTH   (Japan)

^c KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Anti tumor promoter; Asarinin; Asiasarum heterotropoides var. mandshuricum; Lignan; Shouseiryu to; Xanthoxylol

Indexed keywords

ASARININ; LIGNAN; PLANT EXTRACT; SHOUSEIRYU TO; UNCLASSIFIED DRUG; XANTHOXYLOL;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOGENESIS; FEMALE; HERBAL MEDICINE; LUNG TUMOR; MOUSE; NONHUMAN; SKIN TUMOR; TRADITIONAL MEDICINE;

EID: 0030788627     PISSN: 09186158     EISSN: None     Source Type: Journal    
DOI: 10.1248/bpb.20.776     Document Type: Article

References (23)

1. Preliminary report of this work; Konoshima T., Takasaki M., Kozuka M., Tokuda H., Yakugaku Zasshi, 114, 248-256 (1994).
2. Berenblum I., Cancer Res., 1, 807-814 (1941); Yamamoto N., Bister K., ZurHausen H., Nature (London), 278, 553-554 (1979); Verma A. K., Slaga T. J., Wertz P. W., Mueller G. C., Boutwell R. K., Cancer Res. 40, 2367-2371 (1980), and references cited therein.
3. Berenblum I., Cancer Res., 1, 807-814 (1941); Yamamoto N., Bister K., ZurHausen H., Nature (London), 278, 553-554 (1979); Verma A. K., Slaga T. J., Wertz P. W., Mueller G. C., Boutwell R. K., Cancer Res. 40, 2367-2371 (1980), and references cited therein.
4. Berenblum I., Cancer Res., 1, 807-814 (1941); Yamamoto N., Bister K., ZurHausen H., Nature (London), 278, 553-554 (1979); Verma A. K., Slaga T. J., Wertz P. W., Mueller G. C., Boutwell R. K., Cancer Res. 40, 2367-2371 (1980), and references cited therein.
5. Konoshima T., Takasaki M., Kozuka M., Inada A., Nakanishi T., Tokuda H., Matsumoto T., Shouyakugaku Zasshi, 43, 135-141 (1989).
6. Takasaki M., Konoshima T., Kozuka M., Tokuda H., Biol. Pharm. Bull., 18, 435-438 (1995), and references cited therein.
7. Konoshima T., Takasaki M., Tokuda H., Masuda K., Arai Y., Shiojima K., Ageta H., Biol. Pharm. Bull., 19, 962-965 (1996), and references cited therein.
8. Konoshima T., Takasaki M., Tokuda H., Natural Medicines, 50, 158-162 (1996), and references cited therein.
9. Tokuda H., Ohigashi H., Koshimizu K., Ito Y., Cancer Lett., 33, 279-285 (1986); Tokuda H., Konoshima T., Kozuka M., Kimura T., Oncology, 48, 77-80 (1991).
10. Tokuda H., Ohigashi H., Koshimizu K., Ito Y., Cancer Lett., 33, 279-285 (1986); Tokuda H., Konoshima T., Kozuka M., Kimura T., Oncology, 48, 77-80 (1991).
11. 1) was identified as Asiasarum sieboldii, the radix of A. heterotropoides var. mandshuricum, which was commercially available and is the most widely used species, is applied in this report.
12. Hashimoto K., Yanagisawa T., Okui Y., Ikeya M., Maruno M., Fujita T., Planta Med., 60, 124-127 (1994).
13. Ohmoto T., Sung Y., Shouyakugaku Zasshi, 36, 307-314 (1982).
14. Miyazawa M., Ishikawa Y., Toshikura M., Kameoka H., Chem. Express, 6, 703-706 (1991).
15. Hashimoto K., Okada M., Maruno M., Natural Medicines, 48, 39-48 (1994): Saiki Y., Fukuyama H., Tsuneya T., Yakugaku Zasshi, 107, 219-226 (1987); Hashimoto K., Katsuhara T., Itoh H., Ikeya Y., Okada M., Mitsuhashi H., Phytochemistry, 29, 3571-3574 (1990).
16. Hashimoto K., Okada M., Maruno M., Natural Medicines, 48, 39-48 (1994): Saiki Y., Fukuyama H., Tsuneya T., Yakugaku Zasshi, 107, 219-226 (1987); Hashimoto K., Katsuhara T., Itoh H., Ikeya Y., Okada M., Mitsuhashi H., Phytochemistry, 29, 3571-3574 (1990).
17. Hashimoto K., Okada M., Maruno M., Natural Medicines, 48, 39-48 (1994): Saiki Y., Fukuyama H., Tsuneya T., Yakugaku Zasshi, 107, 219-226 (1987); Hashimoto K., Katsuhara T., Itoh H., Ikeya Y., Okada M., Mitsuhashi H., Phytochemistry, 29, 3571-3574 (1990).
18. Henle G., Henle W., J. Bacteriol., 91, 1248-1253 (1966).
19. Inayama Y., Jpn. J. Cancer Res. (Gann), 77, 345-360 (1986).
20. Ohigashi H., Takamura H., Koshimizu K., Tokuda H., Ito Y., Cancer Lett., 30, 143-146 (1986).
21. 2 and 1 × 10 mol ratio/TPA, respectively, and the viability percentage of Raji cells was more than 80% at each concentration; Mizutani K., Kuramoto T., Tamura K., Kozuka M., Tokuda H., Abstracts of Papers, The 113th Annual Meeting of the Pharmaceutical Society of Japan, Osaka, March 1993, Part II, p. 206.
22. In our experiments, when the same amount of glycyrrhetic acid (85 nmol) as 6 or 7 was applied, more than 95% of the mice bore papillomas at 18 weeks of promotion and about 7 papillomas were formed per mouse after 20 weeks of promotion (in the positive control group, 100% of mice bore papillomas at 10 weeks of promotion and more than 10 papillomas were formed per mouse after 20 weeks of promotion, the same as in this report).
23. 1)